EA034244B1 - 1-гетероарил-индолин-4-карбоксамиды в качестве модуляторов gpr52, применяемые для лечения или предотвращения расстройств, связанных с gpr52 - Google Patents

Info

Publication number

EA034244B1

EA034244B1 EA201792375A EA201792375A EA034244B1 EA 034244 B1 EA034244 B1 EA 034244B1 EA 201792375 A EA201792375 A EA 201792375A EA 201792375 A EA201792375 A EA 201792375A EA 034244 B1 EA034244 B1 EA 034244B1

Authority

EA

Eurasian Patent Office

Prior art keywords

pyridin

indoline

carboxamide

fluoro

disorder

Prior art date

2015-04-29

Links

• Espacenet
• Global Dossier
• Discuss

• 238000011282 treatment Methods 0.000 title claims abstract description 56
• 230000002265 prevention Effects 0.000 title description 17
• 150000001875 compounds Chemical class 0.000 claims abstract description 643
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 264
• 238000000034 method Methods 0.000 claims abstract description 141
• 102100033046 G-protein coupled receptor 52 Human genes 0.000 claims abstract description 114
• 230000001404 mediated effect Effects 0.000 claims abstract description 66
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 56
• 201000000980 schizophrenia Diseases 0.000 claims abstract description 43
• 230000037361 pathway Effects 0.000 claims abstract description 42
• 230000000694 effects Effects 0.000 claims abstract description 40
• 208000020925 Bipolar disease Diseases 0.000 claims abstract description 36
• 208000019430 Motor disease Diseases 0.000 claims abstract description 35
• 210000001577 neostriatum Anatomy 0.000 claims abstract description 30
• 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims abstract description 28
• 208000027776 Extrapyramidal disease Diseases 0.000 claims abstract description 22
• 208000027626 Neurocognitive disease Diseases 0.000 claims abstract description 22
• 208000019901 Anxiety disease Diseases 0.000 claims abstract description 21
• 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims abstract description 20
• 208000011117 substance-related disease Diseases 0.000 claims abstract description 19
• 108010057464 Prolactin Proteins 0.000 claims abstract description 18
• 102000003946 Prolactin Human genes 0.000 claims abstract description 18
• 229940097325 prolactin Drugs 0.000 claims abstract description 18
• 208000020401 Depressive disease Diseases 0.000 claims abstract description 17
• 208000023105 Huntington disease Diseases 0.000 claims abstract description 17
• 208000018300 basal ganglia disease Diseases 0.000 claims abstract description 16
• 208000000323 Tourette Syndrome Diseases 0.000 claims abstract description 15
• 208000028017 Psychotic disease Diseases 0.000 claims abstract description 14
• 208000016620 Tourette disease Diseases 0.000 claims abstract description 14
• 208000014674 injury Diseases 0.000 claims abstract description 11
• 208000028173 post-traumatic stress disease Diseases 0.000 claims abstract description 11
• 208000031424 hyperprolactinemia Diseases 0.000 claims abstract description 10
• 208000030990 Impulse-control disease Diseases 0.000 claims abstract description 9
• 208000019022 Mood disease Diseases 0.000 claims abstract description 9
• 208000029560 autism spectrum disease Diseases 0.000 claims abstract description 9
• 206010007776 catatonia Diseases 0.000 claims abstract description 9
• 101000871149 Homo sapiens G-protein coupled receptor 52 Proteins 0.000 claims abstract description 5
• -1 pyridinediyl Chemical group 0.000 claims description 1312
• 208000035475 disorder Diseases 0.000 claims description 236
• 239000003814 drug Substances 0.000 claims description 66
• 150000003839 salts Chemical class 0.000 claims description 65
• 239000000126 substance Substances 0.000 claims description 65
• 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 63
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 58
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 57
• 239000012453 solvate Substances 0.000 claims description 57
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 56
• 208000020016 psychiatric disease Diseases 0.000 claims description 53
• 150000004677 hydrates Chemical class 0.000 claims description 52
• 229940079593 drug Drugs 0.000 claims description 49
• 208000024891 symptom Diseases 0.000 claims description 49
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 40
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 40
• 150000001204 N-oxides Chemical class 0.000 claims description 39
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 39
• 229910052736 halogen Inorganic materials 0.000 claims description 38
• 150000002367 halogens Chemical class 0.000 claims description 38
• 125000004043 oxo group Chemical group O=* 0.000 claims description 37
• 239000000460 chlorine Substances 0.000 claims description 34
• 125000000623 heterocyclic group Chemical group 0.000 claims description 29
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 28
• 125000003118 aryl group Chemical group 0.000 claims description 28
• 125000001072 heteroaryl group Chemical group 0.000 claims description 28
• 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 26
• 125000004244 benzofuran-2-yl group Chemical group [H]C1=C(*)OC2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 26
• 229910052799 carbon Inorganic materials 0.000 claims description 26
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 25
• 125000004533 benzofuran-5-yl group Chemical group O1C=CC2=C1C=CC(=C2)* 0.000 claims description 25
• 230000014509 gene expression Effects 0.000 claims description 25
• 125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 claims description 25
• 239000002904 solvent Substances 0.000 claims description 25
• VUPPNIBEGQJLEG-UHFFFAOYSA-N 2,3-dihydro-1h-indole-4-carboxamide Chemical compound NC(=O)C1=CC=CC2=C1CCN2 VUPPNIBEGQJLEG-UHFFFAOYSA-N 0.000 claims description 24
• 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 24
• QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims description 23
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 22
• 125000000217 alkyl group Chemical group 0.000 claims description 22
• 229910052801 chlorine Inorganic materials 0.000 claims description 22
• 229910052739 hydrogen Inorganic materials 0.000 claims description 18
• DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 claims description 18
• 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 17
• 125000005605 benzo group Chemical group 0.000 claims description 17
• 125000004498 isoxazol-4-yl group Chemical group O1N=CC(=C1)* 0.000 claims description 17
• 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 17
• 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 16
• 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 16
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 16
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 15
• 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims description 14
• 206010000117 Abnormal behaviour Diseases 0.000 claims description 14
• 229910052760 oxygen Inorganic materials 0.000 claims description 14
• 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 13
• 208000012661 Dyskinesia Diseases 0.000 claims description 13
• 230000006399 behavior Effects 0.000 claims description 13
• 230000007585 cortical function Effects 0.000 claims description 13
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 13
• 229910052757 nitrogen Inorganic materials 0.000 claims description 13
• 229910052731 fluorine Inorganic materials 0.000 claims description 12
• 208000024714 major depressive disease Diseases 0.000 claims description 12
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 12
• 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 12
• 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims description 12
• 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 12
• 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 11
• 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims description 11
• 206010013663 drug dependence Diseases 0.000 claims description 11
• 239000011737 fluorine Substances 0.000 claims description 11
• 230000001660 hyperkinetic effect Effects 0.000 claims description 11
• 230000033001 locomotion Effects 0.000 claims description 11
• 125000004361 3,4,5-trifluorophenyl group Chemical group [H]C1=C(F)C(F)=C(F)C([H])=C1* 0.000 claims description 10
• LQSZIELGYRULLD-UHFFFAOYSA-N N-[4-[(3,4,5-trifluorophenyl)methyl]pyridin-2-yl]-2,3-dihydro-1H-indole-4-carboxamide Chemical compound N1CCC=2C(=CC=CC1=2)C(=O)NC1=NC=CC(=C1)CC1=CC(=C(C(=C1)F)F)F LQSZIELGYRULLD-UHFFFAOYSA-N 0.000 claims description 10
• 230000006870 function Effects 0.000 claims description 10
• 230000001965 increasing effect Effects 0.000 claims description 10
• 125000006413 ring segment Chemical group 0.000 claims description 10
• 230000007958 sleep Effects 0.000 claims description 10
• 208000011580 syndromic disease Diseases 0.000 claims description 10
• WGSXKYXKAARAKD-UHFFFAOYSA-N 1-fluoro-3-isocyanato-5-(trifluoromethyl)benzene Chemical group FC1=CC(N=C=O)=CC(C(F)(F)F)=C1 WGSXKYXKAARAKD-UHFFFAOYSA-N 0.000 claims description 9
• 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 9
• 125000003545 alkoxy group Chemical group 0.000 claims description 9
• 230000002829 reductive effect Effects 0.000 claims description 9
• 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims description 8
• 206010043118 Tardive Dyskinesia Diseases 0.000 claims description 8
• RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 8
• 239000003937 drug carrier Substances 0.000 claims description 8
• 208000019116 sleep disease Diseases 0.000 claims description 8
• 230000035882 stress Effects 0.000 claims description 8
• 229910052717 sulfur Inorganic materials 0.000 claims description 8
• 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 claims description 7
• ZVAPWJGRRUHKGP-UHFFFAOYSA-N 1h-1,5-benzodiazepine Chemical compound N1C=CC=NC2=CC=CC=C12 ZVAPWJGRRUHKGP-UHFFFAOYSA-N 0.000 claims description 7
• 206010008748 Chorea Diseases 0.000 claims description 7
• 206010012289 Dementia Diseases 0.000 claims description 7
• 230000002159 abnormal effect Effects 0.000 claims description 7
• 239000002249 anxiolytic agent Substances 0.000 claims description 7
• 208000012601 choreatic disease Diseases 0.000 claims description 7
• 239000000380 hallucinogen Substances 0.000 claims description 7
• 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 7
• 230000015654 memory Effects 0.000 claims description 7
• 230000007106 neurocognition Effects 0.000 claims description 7
• 239000000932 sedative agent Substances 0.000 claims description 7
• 230000001624 sedative effect Effects 0.000 claims description 7
• 230000011273 social behavior Effects 0.000 claims description 7
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 7
• 230000008733 trauma Effects 0.000 claims description 7
• 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 6
• 208000004547 Hallucinations Diseases 0.000 claims description 6
• 206010044565 Tremor Diseases 0.000 claims description 6
• 230000000147 hypnotic effect Effects 0.000 claims description 6
• 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 6
• 239000010802 sludge Substances 0.000 claims description 6
• 208000009017 Athetosis Diseases 0.000 claims description 5
• 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 claims description 5
• 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims description 5
• 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 5
• 208000018839 Wilson disease Diseases 0.000 claims description 5
• 230000000949 anxiolytic effect Effects 0.000 claims description 5
• 239000003048 aphrodisiac agent Substances 0.000 claims description 5
• 230000002509 aphrodisiac effect Effects 0.000 claims description 5
• 239000003176 neuroleptic agent Substances 0.000 claims description 5
• 208000022610 schizoaffective disease Diseases 0.000 claims description 5
• 230000000698 schizophrenic effect Effects 0.000 claims description 5
• 208000016686 tic disease Diseases 0.000 claims description 5
• 206010001540 Akathisia Diseases 0.000 claims description 4
• 206010003591 Ataxia Diseases 0.000 claims description 4
• 206010003694 Atrophy Diseases 0.000 claims description 4
• 208000030336 Bipolar and Related disease Diseases 0.000 claims description 4
• 208000024254 Delusional disease Diseases 0.000 claims description 4
• 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims description 4
• LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 4
• YYBHFEWEJDNRKQ-UHFFFAOYSA-N OCCNC(=O)C=1C=2CCNC=2C=CC=1 Chemical compound OCCNC(=O)C=1C=2CCNC=2C=CC=1 YYBHFEWEJDNRKQ-UHFFFAOYSA-N 0.000 claims description 4
• 208000001431 Psychomotor Agitation Diseases 0.000 claims description 4
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 4
• 206010042008 Stereotypy Diseases 0.000 claims description 4
• 125000003282 alkyl amino group Chemical group 0.000 claims description 4
• 229960001948 caffeine Drugs 0.000 claims description 4
• VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 4
• 125000004122 cyclic group Chemical group 0.000 claims description 4
• 230000006378 damage Effects 0.000 claims description 4
• 125000004663 dialkyl amino group Chemical group 0.000 claims description 4
• 230000008451 emotion Effects 0.000 claims description 4
• 125000001153 fluoro group Chemical group F* 0.000 claims description 4
• 125000005842 heteroatom Chemical group 0.000 claims description 4
• 238000002156 mixing Methods 0.000 claims description 4
• 208000002851 paranoid schizophrenia Diseases 0.000 claims description 4
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
• 208000013623 stereotypic movement disease Diseases 0.000 claims description 4
• 208000006888 Agnosia Diseases 0.000 claims description 3
• 208000008811 Agoraphobia Diseases 0.000 claims description 3
• 208000000044 Amnesia Diseases 0.000 claims description 3
• 208000031091 Amnestic disease Diseases 0.000 claims description 3
• 208000007415 Anhedonia Diseases 0.000 claims description 3
• 206010002942 Apathy Diseases 0.000 claims description 3
• 206010003062 Apraxia Diseases 0.000 claims description 3
• 208000011597 CGF1 Diseases 0.000 claims description 3
• 206010008754 Choreoathetosis Diseases 0.000 claims description 3
• 206010013976 Dyspraxia Diseases 0.000 claims description 3
• 208000011688 Generalised anxiety disease Diseases 0.000 claims description 3
• 206010028403 Mutism Diseases 0.000 claims description 3
• 206010034912 Phobia Diseases 0.000 claims description 3
• 206010039917 Selective mutism Diseases 0.000 claims description 3
• 208000000810 Separation Anxiety Diseases 0.000 claims description 3
• 206010041250 Social phobia Diseases 0.000 claims description 3
• 208000027418 Wounds and injury Diseases 0.000 claims description 3
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 3
• 125000005431 alkyl carboxamide group Chemical group 0.000 claims description 3
• 230000006986 amnesia Effects 0.000 claims description 3
• 230000037444 atrophy Effects 0.000 claims description 3
• 208000029364 generalized anxiety disease Diseases 0.000 claims description 3
• 230000008449 language Effects 0.000 claims description 3
• 230000013016 learning Effects 0.000 claims description 3
• 230000003137 locomotive effect Effects 0.000 claims description 3
• 230000000701 neuroleptic effect Effects 0.000 claims description 3
• 208000019906 panic disease Diseases 0.000 claims description 3
• 208000025874 separation anxiety disease Diseases 0.000 claims description 3
• 208000022925 sleep disturbance Diseases 0.000 claims description 3
• 230000004039 social cognition Effects 0.000 claims description 3
• 201000001716 specific phobia Diseases 0.000 claims description 3
• 238000001228 spectrum Methods 0.000 claims description 3
• ORFUKCGRDYFOFJ-UHFFFAOYSA-N 1-[1-oxido-5-[[3-(trifluoromethyl)phenyl]methyl]pyridin-1-ium-3-yl]-2,3-dihydroindole-4-carboxamide Chemical compound C(N)(=O)C1=C2CCN(C2=CC=C1)C=1C=[N+](C=C(C=1)CC1=CC(=CC=C1)C(F)(F)F)[O-] ORFUKCGRDYFOFJ-UHFFFAOYSA-N 0.000 claims description 2
• 208000020186 Schizophreniform disease Diseases 0.000 claims description 2
• 208000024791 Schizotypal Personality disease Diseases 0.000 claims description 2
• IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 claims description 2
• 125000003158 alcohol group Chemical group 0.000 claims description 2
• 125000004432 carbon atom Chemical group C* 0.000 claims description 2
• 150000003857 carboxamides Chemical class 0.000 claims description 2
• 230000001314 paroxysmal effect Effects 0.000 claims description 2
• 229940049953 phenylacetate Drugs 0.000 claims description 2
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 4
• SHTHWCQBJTUESB-UHFFFAOYSA-N ethyl hypofluorite Chemical compound CCOF SHTHWCQBJTUESB-UHFFFAOYSA-N 0.000 claims 2
• 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
• 241000208125 Nicotiana Species 0.000 claims 1
• 240000004308 marijuana Species 0.000 claims 1
• WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 claims 1
• 208000000269 Hyperkinesis Diseases 0.000 abstract description 6
• 208000020685 sleep-wake disease Diseases 0.000 abstract description 6
• 230000003542 behavioural effect Effects 0.000 abstract description 4
• 206010011168 Cortical dysfunction Diseases 0.000 abstract description 2
• 208000016285 Movement disease Diseases 0.000 abstract description 2
• 230000003247 decreasing effect Effects 0.000 abstract description 2
• 230000009461 neurocognitive dysfunction Effects 0.000 abstract description 2
• 208000027691 Conduct disease Diseases 0.000 abstract 1
• 230000005856 abnormality Effects 0.000 abstract 1
• 208000035548 disruptive behavior disease Diseases 0.000 abstract 1
• 230000005032 impulse control Effects 0.000 abstract 1
• 101710108870 G-protein coupled receptor 52 Proteins 0.000 description 110
• 238000002360 preparation method Methods 0.000 description 78
• 239000000203 mixture Substances 0.000 description 57
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 54
• 238000005481 NMR spectroscopy Methods 0.000 description 53
• 210000004556 brain Anatomy 0.000 description 41
• 239000007787 solid Substances 0.000 description 38
• 239000000243 solution Substances 0.000 description 34
• 239000000825 pharmaceutical preparation Substances 0.000 description 31
• 229940127557 pharmaceutical product Drugs 0.000 description 30
• 241000700159 Rattus Species 0.000 description 29
• 210000004027 cell Anatomy 0.000 description 29
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
• 239000002552 dosage form Substances 0.000 description 27
• 238000003786 synthesis reaction Methods 0.000 description 26
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 24
• BXDZOYLPNAIDOC-UHFFFAOYSA-N N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]-1-[2-[2-[2-[2-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethoxy]ethoxy]ethoxy]ethylamino]-2-oxoethyl]piperidine-4-carboxamide Chemical compound CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCN(CC(=O)NCCOCCOCCOCCNc4cccc5C(=O)N(C6CCC(=O)NC6=O)C(=O)c45)CC3)s2)o1 BXDZOYLPNAIDOC-UHFFFAOYSA-N 0.000 description 23
• 230000015572 biosynthetic process Effects 0.000 description 22
• 201000010099 disease Diseases 0.000 description 22
• 238000005516 engineering process Methods 0.000 description 22
• UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 20
• 239000000556 agonist Substances 0.000 description 19
• 238000004519 manufacturing process Methods 0.000 description 19
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
• 239000004480 active ingredient Substances 0.000 description 18
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 16
• 239000007788 liquid Substances 0.000 description 16
• 239000000843 powder Substances 0.000 description 16
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 15
• 102000005962 receptors Human genes 0.000 description 15
• 108020003175 receptors Proteins 0.000 description 15
• 239000000523 sample Substances 0.000 description 15
• 239000000725 suspension Substances 0.000 description 15
• 210000001519 tissue Anatomy 0.000 description 15
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
• 241000699670 Mus sp. Species 0.000 description 14
• 125000004429 atom Chemical group 0.000 description 14
• LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 14
• 239000011541 reaction mixture Substances 0.000 description 14
• 239000003826 tablet Substances 0.000 description 14
• QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
• 239000010410 layer Substances 0.000 description 13
• 150000003254 radicals Chemical class 0.000 description 13
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
• IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 12
• 239000002775 capsule Substances 0.000 description 12
• 238000006243 chemical reaction Methods 0.000 description 12
• 229960003638 dopamine Drugs 0.000 description 12
• 229910052740 iodine Inorganic materials 0.000 description 12
• 230000002285 radioactive effect Effects 0.000 description 12
• 239000005557 antagonist Substances 0.000 description 11
• 235000019439 ethyl acetate Nutrition 0.000 description 11
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 11
• 239000012071 phase Substances 0.000 description 11
• 125000001424 substituent group Chemical group 0.000 description 11
• 210000003169 central nervous system Anatomy 0.000 description 10
• 239000000902 placebo Substances 0.000 description 10
• 229940068196 placebo Drugs 0.000 description 10
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
• 101150049660 DRD2 gene Proteins 0.000 description 9
• 241000282412 Homo Species 0.000 description 9
• 241000699666 Mus <mouse, genus> Species 0.000 description 9
• 241000283984 Rodentia Species 0.000 description 9
• 239000000164 antipsychotic agent Substances 0.000 description 9
• 239000000872 buffer Substances 0.000 description 9
• 239000003153 chemical reaction reagent Substances 0.000 description 9
• 238000004440 column chromatography Methods 0.000 description 9
• 238000009826 distribution Methods 0.000 description 9
• 108020004999 messenger RNA Proteins 0.000 description 9
• KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
• 108090000623 proteins and genes Proteins 0.000 description 9
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
• 206010012335 Dependence Diseases 0.000 description 8
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
• 238000004458 analytical method Methods 0.000 description 8
• 230000000875 corresponding effect Effects 0.000 description 8
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
• 239000000543 intermediate Substances 0.000 description 8
• 230000000155 isotopic effect Effects 0.000 description 8
• 239000002953 phosphate buffered saline Substances 0.000 description 8
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 7
• YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 7
• 206010026749 Mania Diseases 0.000 description 7
• 208000018737 Parkinson disease Diseases 0.000 description 7
• 239000002253 acid Substances 0.000 description 7
• 230000000561 anti-psychotic effect Effects 0.000 description 7
• 125000003636 chemical group Chemical group 0.000 description 7
• 230000001054 cortical effect Effects 0.000 description 7
• 239000013078 crystal Substances 0.000 description 7
• 229910052805 deuterium Inorganic materials 0.000 description 7
• 125000001188 haloalkyl group Chemical group 0.000 description 7
• 229960003878 haloperidol Drugs 0.000 description 7
• 239000002609 medium Substances 0.000 description 7
• 210000002569 neuron Anatomy 0.000 description 7
• 210000004940 nucleus Anatomy 0.000 description 7
• 230000000144 pharmacologic effect Effects 0.000 description 7
• 238000003753 real-time PCR Methods 0.000 description 7
• 239000011734 sodium Substances 0.000 description 7
• KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 6
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 6
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 6
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
• 241001465754 Metazoa Species 0.000 description 6
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 6
• 229940025084 amphetamine Drugs 0.000 description 6
• 230000003935 attention Effects 0.000 description 6
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 6
• 238000004128 high performance liquid chromatography Methods 0.000 description 6
• 238000007901 in situ hybridization Methods 0.000 description 6
• 238000002347 injection Methods 0.000 description 6
• 239000007924 injection Substances 0.000 description 6
• 238000004811 liquid chromatography Methods 0.000 description 6
• 230000000926 neurological effect Effects 0.000 description 6
• 239000003921 oil Substances 0.000 description 6
• 239000012044 organic layer Substances 0.000 description 6
• 230000007170 pathology Effects 0.000 description 6
• 239000000651 prodrug Substances 0.000 description 6
• 229940002612 prodrug Drugs 0.000 description 6
• 102000004169 proteins and genes Human genes 0.000 description 6
• 229920006395 saturated elastomer Polymers 0.000 description 6
• 238000003756 stirring Methods 0.000 description 6
• 238000006467 substitution reaction Methods 0.000 description 6
• 238000001308 synthesis method Methods 0.000 description 6
• FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
• 229910052722 tritium Inorganic materials 0.000 description 6
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
• 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 5
• 102000012749 Dopamine and cAMP-Regulated Phosphoprotein 32 Human genes 0.000 description 5
• 108010090047 Dopamine and cAMP-Regulated Phosphoprotein 32 Proteins 0.000 description 5
• 241000124008 Mammalia Species 0.000 description 5
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
• 125000002252 acyl group Chemical group 0.000 description 5
• 239000000654 additive Substances 0.000 description 5
• 239000000443 aerosol Substances 0.000 description 5
• 239000000935 antidepressant agent Substances 0.000 description 5
• 229940005513 antidepressants Drugs 0.000 description 5
• 229940005529 antipsychotics Drugs 0.000 description 5
• 239000000969 carrier Substances 0.000 description 5
• 230000004186 co-expression Effects 0.000 description 5
• 239000000839 emulsion Substances 0.000 description 5
• 230000003834 intracellular effect Effects 0.000 description 5
• 239000012528 membrane Substances 0.000 description 5
• 231100000252 nontoxic Toxicity 0.000 description 5
• 230000003000 nontoxic effect Effects 0.000 description 5
• 239000012074 organic phase Substances 0.000 description 5
• 239000002244 precipitate Substances 0.000 description 5
• 239000002243 precursor Substances 0.000 description 5
• 210000002442 prefrontal cortex Anatomy 0.000 description 5
• 230000008569 process Effects 0.000 description 5
• 239000000047 product Substances 0.000 description 5
• 229910052938 sodium sulfate Inorganic materials 0.000 description 5
• 235000011152 sodium sulphate Nutrition 0.000 description 5
• 239000007921 spray Substances 0.000 description 5
• 238000000967 suction filtration Methods 0.000 description 5
• 239000000375 suspending agent Substances 0.000 description 5
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
• 208000007848 Alcoholism Diseases 0.000 description 4
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
• 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 4
• 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 4
• 238000002965 ELISA Methods 0.000 description 4
• 229940124001 GPR52 agonist Drugs 0.000 description 4
• 108010010803 Gelatin Proteins 0.000 description 4
• MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
• 208000012902 Nervous system disease Diseases 0.000 description 4
• 244000061176 Nicotiana tabacum Species 0.000 description 4
• 238000010521 absorption reaction Methods 0.000 description 4
• 230000004913 activation Effects 0.000 description 4
• 230000001154 acute effect Effects 0.000 description 4
• 125000004423 acyloxy group Chemical group 0.000 description 4
• 229910021529 ammonia Inorganic materials 0.000 description 4
• 210000004727 amygdala Anatomy 0.000 description 4
• 238000003556 assay Methods 0.000 description 4
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
• 230000008901 benefit Effects 0.000 description 4
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
• 229910052794 bromium Inorganic materials 0.000 description 4
• 208000010877 cognitive disease Diseases 0.000 description 4
• 239000003086 colorant Substances 0.000 description 4
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
• 239000007789 gas Substances 0.000 description 4
• 238000004817 gas chromatography Methods 0.000 description 4
• 239000000499 gel Substances 0.000 description 4
• 229920000159 gelatin Polymers 0.000 description 4
• 235000019322 gelatine Nutrition 0.000 description 4
• 235000011852 gelatine desserts Nutrition 0.000 description 4
• 230000036541 health Effects 0.000 description 4
• 210000001320 hippocampus Anatomy 0.000 description 4
• 239000011630 iodine Substances 0.000 description 4
• QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 4
• 229910052744 lithium Inorganic materials 0.000 description 4
• 239000007937 lozenge Substances 0.000 description 4
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
• 229910052751 metal Inorganic materials 0.000 description 4
• 239000002184 metal Substances 0.000 description 4
• 229920000609 methyl cellulose Polymers 0.000 description 4
• 239000001923 methylcellulose Substances 0.000 description 4
• 235000010981 methylcellulose Nutrition 0.000 description 4
• 239000001301 oxygen Substances 0.000 description 4
• 239000008188 pellet Substances 0.000 description 4
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
• 229920003023 plastic Polymers 0.000 description 4
• 239000004033 plastic Substances 0.000 description 4
• 229910052700 potassium Inorganic materials 0.000 description 4
• 239000003755 preservative agent Substances 0.000 description 4
• 238000011321 prophylaxis Methods 0.000 description 4
• 125000006239 protecting group Chemical group 0.000 description 4
• 125000000714 pyrimidinyl group Chemical group 0.000 description 4
• 201000009032 substance abuse Diseases 0.000 description 4
• 238000012360 testing method Methods 0.000 description 4
• FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• 239000002562 thickening agent Substances 0.000 description 4
• 238000004809 thin layer chromatography Methods 0.000 description 4
• SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 3
• ACHZLWIUAPEAHI-UHFFFAOYSA-N (5-fluoroindol-1-yl)-tri(propan-2-yl)silane Chemical compound FC1=CC=C2N([Si](C(C)C)(C(C)C)C(C)C)C=CC2=C1 ACHZLWIUAPEAHI-UHFFFAOYSA-N 0.000 description 3
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
• XRCWJOJFHVBVQC-UHFFFAOYSA-N 1-[4-(hydroxymethyl)pyridin-2-yl]-2,3-dihydroindole-4-carboxylic acid Chemical compound OCC1=CC(=NC=C1)N1CCC=2C(=CC=CC1=2)C(=O)O XRCWJOJFHVBVQC-UHFFFAOYSA-N 0.000 description 3
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• 241000218236 Cannabis Species 0.000 description 3
• 208000028698 Cognitive impairment Diseases 0.000 description 3
• 229920002261 Corn starch Polymers 0.000 description 3
• 102000016911 Deoxyribonucleases Human genes 0.000 description 3
• 108010053770 Deoxyribonucleases Proteins 0.000 description 3
• SKQACAXLFJEEMJ-UHFFFAOYSA-N FC1=C(C=2CCNC=2C=C1)C(=O)OC Chemical compound FC1=C(C=2CCNC=2C=C1)C(=O)OC SKQACAXLFJEEMJ-UHFFFAOYSA-N 0.000 description 3
• 102100035902 Glutamate decarboxylase 1 Human genes 0.000 description 3
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
• 206010020651 Hyperkinesia Diseases 0.000 description 3
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
• 208000002033 Myoclonus Diseases 0.000 description 3
• 206010028813 Nausea Diseases 0.000 description 3
• 208000025966 Neurological disease Diseases 0.000 description 3
• 206010062519 Poor quality sleep Diseases 0.000 description 3
• 239000004146 Propane-1,2-diol Substances 0.000 description 3
• 208000013200 Stress disease Diseases 0.000 description 3
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
• 150000007513 acids Chemical class 0.000 description 3
• 230000001430 anti-depressive effect Effects 0.000 description 3
• 230000036506 anxiety Effects 0.000 description 3
• 239000007864 aqueous solution Substances 0.000 description 3
• 239000002585 base Substances 0.000 description 3
• 239000011230 binding agent Substances 0.000 description 3
• 239000012267 brine Substances 0.000 description 3
• 239000001768 carboxy methyl cellulose Substances 0.000 description 3
• 210000005056 cell body Anatomy 0.000 description 3
• 210000001638 cerebellum Anatomy 0.000 description 3
• 230000008859 change Effects 0.000 description 3
• 239000003795 chemical substances by application Substances 0.000 description 3
• 230000001684 chronic effect Effects 0.000 description 3
• 229960003920 cocaine Drugs 0.000 description 3
• 239000008120 corn starch Substances 0.000 description 3
• 239000006071 cream Substances 0.000 description 3
• 230000007423 decrease Effects 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 238000011161 development Methods 0.000 description 3
• 239000003085 diluting agent Substances 0.000 description 3
• 239000002270 dispersing agent Substances 0.000 description 3
• WDUDHEOUGWAKFD-UHFFFAOYSA-N ditert-butyl(cyclopenta-2,4-dien-1-yl)phosphane;iron(2+) Chemical compound [Fe+2].CC(C)(C)P(C(C)(C)C)C1=CC=C[CH-]1.CC(C)(C)P(C(C)(C)C)C1=CC=C[CH-]1 WDUDHEOUGWAKFD-UHFFFAOYSA-N 0.000 description 3
• 230000004064 dysfunction Effects 0.000 description 3
• 238000002474 experimental method Methods 0.000 description 3
• 239000000706 filtrate Substances 0.000 description 3
• 239000012634 fragment Substances 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 230000001744 histochemical effect Effects 0.000 description 3
• 238000009396 hybridization Methods 0.000 description 3
• 239000001257 hydrogen Substances 0.000 description 3
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
• IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
• 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
• 210000003016 hypothalamus Anatomy 0.000 description 3
• 239000002117 illicit drug Substances 0.000 description 3
• 230000006872 improvement Effects 0.000 description 3
• 238000001727 in vivo Methods 0.000 description 3
• 239000004615 ingredient Substances 0.000 description 3
• 230000002401 inhibitory effect Effects 0.000 description 3
• 230000005764 inhibitory process Effects 0.000 description 3
• 238000011813 knockout mouse model Methods 0.000 description 3
• 239000008101 lactose Substances 0.000 description 3
• 230000006742 locomotor activity Effects 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 230000003340 mental effect Effects 0.000 description 3
• 230000008693 nausea Effects 0.000 description 3
• 229960002715 nicotine Drugs 0.000 description 3
• SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 3
• 229910052763 palladium Inorganic materials 0.000 description 3
• 239000002245 particle Substances 0.000 description 3
• 239000000546 pharmaceutical excipient Substances 0.000 description 3
• JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 3
• 229950010883 phencyclidine Drugs 0.000 description 3
• 239000006187 pill Substances 0.000 description 3
• 230000006977 prepulse inhibition Effects 0.000 description 3
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
• 238000000746 purification Methods 0.000 description 3
• 125000004076 pyridyl group Chemical group 0.000 description 3
• 230000004044 response Effects 0.000 description 3
• 238000005070 sampling Methods 0.000 description 3
• 238000012216 screening Methods 0.000 description 3
• 230000008054 signal transmission Effects 0.000 description 3
• 239000000741 silica gel Substances 0.000 description 3
• 229910002027 silica gel Inorganic materials 0.000 description 3
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
• 239000003381 stabilizer Substances 0.000 description 3
• 239000000829 suppository Substances 0.000 description 3
• 230000001225 therapeutic effect Effects 0.000 description 3
• 238000013518 transcription Methods 0.000 description 3
• 230000035897 transcription Effects 0.000 description 3
• AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
• AHOUBRCZNHFOSL-SVLNYFRSSA-N (3s,4r)-3-[(2,2-dideuterio-1,3-benzodioxol-5-yl)oxymethyl]-4-(4-fluorophenyl)piperidine Chemical compound C1([C@@H]2CCNC[C@H]2COC2=CC=C3OC(OC3=C2)([2H])[2H])=CC=C(F)C=C1 AHOUBRCZNHFOSL-SVLNYFRSSA-N 0.000 description 2
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
• OIFAHDAXIUURLN-UHFFFAOYSA-N 2-(fluoromethyl)oxirane Chemical compound FCC1CO1 OIFAHDAXIUURLN-UHFFFAOYSA-N 0.000 description 2
• ATRQECRSCHYSNP-UHFFFAOYSA-N 2-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=CC=N1 ATRQECRSCHYSNP-UHFFFAOYSA-N 0.000 description 2
• BQDUNOMMYOKHEP-GQALSZNTSA-N 3-(2,5-difluorophenyl)-7-[1,1,1,3,3,3-hexadeuterio-2-(trideuteriomethyl)propan-2-yl]-6-[(2-methyl-1,2,4-triazol-3-yl)methoxy]-[1,2,4]triazolo[4,3-b]pyridazine Chemical compound N12N=C(OCC=3N(N=CN=3)C)C(C(C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])=CC2=NN=C1C1=CC(F)=CC=C1F BQDUNOMMYOKHEP-GQALSZNTSA-N 0.000 description 2
• ZSNJLCRNTPIMLT-UHFFFAOYSA-N 5-fluoro-1-tri(propan-2-yl)silylindole-4-carboxylic acid Chemical compound FC1=CC=C2N([Si](C(C)C)(C(C)C)C(C)C)C=CC2=C1C(O)=O ZSNJLCRNTPIMLT-UHFFFAOYSA-N 0.000 description 2
• 244000215068 Acacia senegal Species 0.000 description 2
• 102000007469 Actins Human genes 0.000 description 2
• 108010085238 Actins Proteins 0.000 description 2
• 206010003805 Autism Diseases 0.000 description 2
• 208000020706 Autistic disease Diseases 0.000 description 2
• GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 2
• 108091006146 Channels Proteins 0.000 description 2
• 208000022497 Cocaine-Related disease Diseases 0.000 description 2
• 108020004414 DNA Proteins 0.000 description 2
• 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 2
• 206010013654 Drug abuse Diseases 0.000 description 2
• 208000014094 Dystonic disease Diseases 0.000 description 2
• 208000010228 Erectile Dysfunction Diseases 0.000 description 2
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
• 229920000084 Gum arabic Polymers 0.000 description 2
• 101000873546 Homo sapiens Glutamate decarboxylase 1 Proteins 0.000 description 2
• 206010021082 Hypoprolactinaemia Diseases 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
• 208000003863 Marijuana Abuse Diseases 0.000 description 2
• 208000001145 Metabolic Syndrome Diseases 0.000 description 2
• BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
• 101100122781 Mus musculus Gpr52 gene Proteins 0.000 description 2
• QQQIECGTIMUVDS-UHFFFAOYSA-N N-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-3,4-dimethoxybenzamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NCC1=CC=C(OCCN(C)C)C=C1 QQQIECGTIMUVDS-UHFFFAOYSA-N 0.000 description 2
• ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
• 208000026251 Opioid-Related disease Diseases 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 229930040373 Paraformaldehyde Natural products 0.000 description 2
• 208000006199 Parasomnias Diseases 0.000 description 2
• AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• 208000006011 Stroke Diseases 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
• 229920001615 Tragacanth Polymers 0.000 description 2
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
• 206010047700 Vomiting Diseases 0.000 description 2
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
• 235000010489 acacia gum Nutrition 0.000 description 2
• 239000000205 acacia gum Substances 0.000 description 2
• 239000008186 active pharmaceutical agent Substances 0.000 description 2
• 238000011360 adjunctive therapy Methods 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 201000007930 alcohol dependence Diseases 0.000 description 2
• 150000001299 aldehydes Chemical group 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 230000037007 arousal Effects 0.000 description 2
• 238000003149 assay kit Methods 0.000 description 2
• 239000000305 astragalus gummifer gum Substances 0.000 description 2
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 208000028683 bipolar I disease Diseases 0.000 description 2
• 208000025307 bipolar depression Diseases 0.000 description 2
• 244000309464 bull Species 0.000 description 2
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
• 229910000024 caesium carbonate Inorganic materials 0.000 description 2
• 235000011089 carbon dioxide Nutrition 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 210000003710 cerebral cortex Anatomy 0.000 description 2
• KQIADDMXRMTWHZ-UHFFFAOYSA-N chloro-tri(propan-2-yl)silane Chemical compound CC(C)[Si](Cl)(C(C)C)C(C)C KQIADDMXRMTWHZ-UHFFFAOYSA-N 0.000 description 2
• 201000006145 cocaine dependence Diseases 0.000 description 2
• 229940110456 cocoa butter Drugs 0.000 description 2
• 235000019868 cocoa butter Nutrition 0.000 description 2
• 230000001149 cognitive effect Effects 0.000 description 2
• 238000004590 computer program Methods 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 238000002425 crystallisation Methods 0.000 description 2
• 230000008025 crystallization Effects 0.000 description 2
• 208000026725 cyclothymic disease Diseases 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• 239000012954 diazonium Substances 0.000 description 2
• 235000014113 dietary fatty acids Nutrition 0.000 description 2
• CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
• 239000007884 disintegrant Substances 0.000 description 2
• 210000001029 dorsal striatum Anatomy 0.000 description 2
• 238000001035 drying Methods 0.000 description 2
• 208000024732 dysthymic disease Diseases 0.000 description 2
• 208000010118 dystonia Diseases 0.000 description 2
• 238000000132 electrospray ionisation Methods 0.000 description 2
• 230000008030 elimination Effects 0.000 description 2
• 238000003379 elimination reaction Methods 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 150000002148 esters Chemical group 0.000 description 2
• 238000001704 evaporation Methods 0.000 description 2
• 230000008020 evaporation Effects 0.000 description 2
• 238000013213 extrapolation Methods 0.000 description 2
• 239000000194 fatty acid Substances 0.000 description 2
• 229930195729 fatty acid Natural products 0.000 description 2
• 238000011049 filling Methods 0.000 description 2
• 125000000524 functional group Chemical group 0.000 description 2
• 238000002599 functional magnetic resonance imaging Methods 0.000 description 2
• 125000002541 furyl group Chemical group 0.000 description 2
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 230000005802 health problem Effects 0.000 description 2
• 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 2
• 238000000265 homogenisation Methods 0.000 description 2
• 150000002483 hydrogen compounds Chemical class 0.000 description 2
• 238000005984 hydrogenation reaction Methods 0.000 description 2
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
• 238000003384 imaging method Methods 0.000 description 2
• 125000002632 imidazolidinyl group Chemical group 0.000 description 2
• 125000002883 imidazolyl group Chemical group 0.000 description 2
• 238000007654 immersion Methods 0.000 description 2
• 201000001881 impotence Diseases 0.000 description 2
• 230000001976 improved effect Effects 0.000 description 2
• 238000000338 in vitro Methods 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 125000001041 indolyl group Chemical group 0.000 description 2
• 208000000509 infertility Diseases 0.000 description 2
• 230000036512 infertility Effects 0.000 description 2
• 231100000535 infertility Toxicity 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 230000035987 intoxication Effects 0.000 description 2
• 231100000566 intoxication Toxicity 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
• PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
• 125000000842 isoxazolyl group Chemical group 0.000 description 2
• 229960005302 itopride Drugs 0.000 description 2
• 150000002576 ketones Chemical group 0.000 description 2
• 150000002596 lactones Chemical group 0.000 description 2
• 230000004807 localization Effects 0.000 description 2
• 239000006210 lotion Substances 0.000 description 2
• 239000000314 lubricant Substances 0.000 description 2
• 239000012139 lysis buffer Substances 0.000 description 2
• 235000019359 magnesium stearate Nutrition 0.000 description 2
• 238000013227 male C57BL/6J mice Methods 0.000 description 2
• 238000004949 mass spectrometry Methods 0.000 description 2
• 239000011159 matrix material Substances 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• 210000001767 medulla oblongata Anatomy 0.000 description 2
• 238000002844 melting Methods 0.000 description 2
• 206010027175 memory impairment Diseases 0.000 description 2
• 210000001259 mesencephalon Anatomy 0.000 description 2
• 150000002739 metals Chemical class 0.000 description 2
• AOWXPFSYLFDFHC-UHFFFAOYSA-N methyl 2,3-dihydro-1h-indole-4-carboxylate Chemical compound COC(=O)C1=CC=CC2=C1CCN2 AOWXPFSYLFDFHC-UHFFFAOYSA-N 0.000 description 2
• 235000013336 milk Nutrition 0.000 description 2
• 239000008267 milk Substances 0.000 description 2
• 210000004080 milk Anatomy 0.000 description 2
• 230000003020 moisturizing effect Effects 0.000 description 2
• 238000012544 monitoring process Methods 0.000 description 2
• 239000004050 mood stabilizer Substances 0.000 description 2
• 229940127237 mood stabilizer Drugs 0.000 description 2
• 125000001624 naphthyl group Chemical group 0.000 description 2
• 210000003928 nasal cavity Anatomy 0.000 description 2
• 239000006199 nebulizer Substances 0.000 description 2
• 239000000346 nonvolatile oil Substances 0.000 description 2
• 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 239000002751 oligonucleotide probe Substances 0.000 description 2
• 150000007530 organic bases Chemical class 0.000 description 2
• 125000003566 oxetanyl group Chemical group 0.000 description 2
• 125000004430 oxygen atom Chemical group O* 0.000 description 2
• YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
• 229920002866 paraformaldehyde Polymers 0.000 description 2
• 239000006201 parenteral dosage form Substances 0.000 description 2
• 229960002296 paroxetine Drugs 0.000 description 2
• 230000002085 persistent effect Effects 0.000 description 2
• 125000003386 piperidinyl group Chemical group 0.000 description 2
• 239000013612 plasmid Substances 0.000 description 2
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
• 239000011591 potassium Substances 0.000 description 2
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
• 229920001592 potato starch Polymers 0.000 description 2
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 2
• 239000003380 propellant Substances 0.000 description 2
• DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
• 239000011241 protective layer Substances 0.000 description 2
• 229940124811 psychiatric drug Drugs 0.000 description 2
• 125000003226 pyrazolyl group Chemical group 0.000 description 2
• 238000012797 qualification Methods 0.000 description 2
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
• 230000005855 radiation Effects 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 238000006722 reduction reaction Methods 0.000 description 2
• 210000002345 respiratory system Anatomy 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 230000006403 short-term memory Effects 0.000 description 2
• 238000009097 single-agent therapy Methods 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 2
• 238000010186 staining Methods 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 231100000736 substance abuse Toxicity 0.000 description 2
• 210000003523 substantia nigra Anatomy 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 239000011593 sulfur Substances 0.000 description 2
• 230000008093 supporting effect Effects 0.000 description 2
• 230000015883 synaptic transmission, dopaminergic Effects 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 210000001103 thalamus Anatomy 0.000 description 2
• AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
• 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 2
• 229940102566 valproate Drugs 0.000 description 2
• 210000001030 ventral striatum Anatomy 0.000 description 2
• 230000008673 vomiting Effects 0.000 description 2
• OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
• BTOJYCTUJJHANF-PBHICJAKSA-N (1r,2s)-5-methoxy-1-methyl-n,n-dipropyl-1,2,3,4-tetrahydronaphthalen-2-amine Chemical compound C1=CC=C2[C@@H](C)[C@@H](N(CCC)CCC)CCC2=C1OC BTOJYCTUJJHANF-PBHICJAKSA-N 0.000 description 1
• GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
• IDSWHVZEQHESIJ-SCSAIBSYSA-N (2r)-1-amino-3-methoxypropan-2-ol Chemical compound COC[C@H](O)CN IDSWHVZEQHESIJ-SCSAIBSYSA-N 0.000 description 1
• DTXCSCJRPZOOAQ-VKHMYHEASA-N (2s)-3-amino-2-fluoropropan-1-ol Chemical compound NC[C@H](F)CO DTXCSCJRPZOOAQ-VKHMYHEASA-N 0.000 description 1
• OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
• PVPBBTJXIKFICP-UHFFFAOYSA-N (7-aminophenothiazin-3-ylidene)azanium;chloride Chemical compound [Cl-].C1=CC(=[NH2+])C=C2SC3=CC(N)=CC=C3N=C21 PVPBBTJXIKFICP-UHFFFAOYSA-N 0.000 description 1
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
• DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
• KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
• FIARMZDBEGVMLV-UHFFFAOYSA-N 1,1,2,2,2-pentafluoroethanolate Chemical group [O-]C(F)(F)C(F)(F)F FIARMZDBEGVMLV-UHFFFAOYSA-N 0.000 description 1
• 125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 description 1
• YAXWOADCWUUUNX-UHFFFAOYSA-N 1,2,2,3-tetramethylpiperidine Chemical compound CC1CCCN(C)C1(C)C YAXWOADCWUUUNX-UHFFFAOYSA-N 0.000 description 1
• 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
• DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
• MAJWDNIRYJWIQU-UHFFFAOYSA-N 1,4-diphenylbutane-2,3-diamine Chemical compound C=1C=CC=CC=1CC(N)C(N)CC1=CC=CC=C1 MAJWDNIRYJWIQU-UHFFFAOYSA-N 0.000 description 1
• WMFACUQHPBZUMK-FQEVSTJZSA-N 1-[1-oxido-5-[[3-(trifluoromethyl)phenyl]methyl]pyridin-1-ium-3-yl]-N-[(3S)-oxolan-3-yl]-2,3-dihydroindole-4-carboxamide Chemical compound O1C[C@H](CC1)NC(=O)C1=C2CCN(C2=CC=C1)C=1C=[N+](C=C(C=1)CC1=CC(=CC=C1)C(F)(F)F)[O-] WMFACUQHPBZUMK-FQEVSTJZSA-N 0.000 description 1
• PLAOWKHMIBWRNT-UHFFFAOYSA-N 1-[4-(chloromethyl)pyridin-2-yl]-2,3-dihydroindole-4-carboxylic acid Chemical compound ClCC1=CC(=NC=C1)N1CCC=2C(=CC=CC1=2)C(=O)O PLAOWKHMIBWRNT-UHFFFAOYSA-N 0.000 description 1
• XEWIYNJTSFAXSH-UHFFFAOYSA-N 1-[5-[[3-(trifluoromethyl)phenyl]methyl]pyridin-3-yl]-2,3-dihydroindole-4-carboxamide Chemical compound FC(C=1C=C(CC=2C=C(C=NC=2)N2CCC=3C(=CC=CC2=3)C(=O)N)C=CC=1)(F)F XEWIYNJTSFAXSH-UHFFFAOYSA-N 0.000 description 1
• WYXQQAYIAJRORT-UHFFFAOYSA-N 1-benzofuran-5-ylboronic acid Chemical compound OB(O)C1=CC=C2OC=CC2=C1 WYXQQAYIAJRORT-UHFFFAOYSA-N 0.000 description 1
• 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
• RKMGAJGJIURJSJ-UHFFFAOYSA-N 2,2,6,6-Tetramethylpiperidine Substances CC1(C)CCCC(C)(C)N1 RKMGAJGJIURJSJ-UHFFFAOYSA-N 0.000 description 1
• YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
• WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
• TVSLNRQODQRVJZ-UHFFFAOYSA-N 2-(3,4,5-trifluorophenyl)acetonitrile Chemical group FC1=CC(CC#N)=CC(F)=C1F TVSLNRQODQRVJZ-UHFFFAOYSA-N 0.000 description 1
• VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
• UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
• SFDYIRNUWWERSW-UHFFFAOYSA-N 2-chloro-4-[[3-(trifluoromethyl)phenyl]methyl]pyridine Chemical compound ClC1=NC=CC(=C1)CC1=CC(=CC=C1)C(F)(F)F SFDYIRNUWWERSW-UHFFFAOYSA-N 0.000 description 1
• HYBHTQQTNKRJSV-UHFFFAOYSA-N 2-chloro-6-[[3-(trifluoromethyl)phenyl]methyl]pyridine Chemical compound ClC1=NC(=CC=C1)CC1=CC(=CC=C1)C(F)(F)F HYBHTQQTNKRJSV-UHFFFAOYSA-N 0.000 description 1
• LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
• 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• WAOQONBSWFLFPE-VIFPVBQESA-N 3,5-dichloro-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2-hydroxy-6-methoxybenzamide Chemical compound CCN1CCC[C@H]1CNC(=O)C1=C(O)C(Cl)=CC(Cl)=C1OC WAOQONBSWFLFPE-VIFPVBQESA-N 0.000 description 1
• SCURCOWZQJIUGR-UHFFFAOYSA-N 3-(trifluoromethyl)benzenethiol Chemical compound FC(F)(F)C1=CC=CC(S)=C1 SCURCOWZQJIUGR-UHFFFAOYSA-N 0.000 description 1
• NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
• LLBLNMUONVVVPG-UHFFFAOYSA-N 4-(4-chlorophenyl)-1-(1H-indol-3-ylmethyl)-4-piperidinol Chemical compound C1CN(CC=2C3=CC=CC=C3NC=2)CCC1(O)C1=CC=C(Cl)C=C1 LLBLNMUONVVVPG-UHFFFAOYSA-N 0.000 description 1
• XHJAOEKASUFHHN-UHFFFAOYSA-N 5-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=C=NC=C[CH]1 XHJAOEKASUFHHN-UHFFFAOYSA-N 0.000 description 1
• XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
• INNWVRBZMBCEJI-UHFFFAOYSA-N 5-phenyl-2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diol;hydrobromide Chemical compound Br.C1=2C=C(O)C(O)=CC=2CCNCC1C1=CC=CC=C1 INNWVRBZMBCEJI-UHFFFAOYSA-N 0.000 description 1
• KKZGFVAZUKHFAC-UHFFFAOYSA-N 6-br-apb Chemical compound C1N(CC=C)CCC=2C(Br)=C(O)C(O)=CC=2C1C1=CC=CC=C1 KKZGFVAZUKHFAC-UHFFFAOYSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• GHWJEDJMOVUXEC-UHFFFAOYSA-N 9-chloro-5-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol Chemical compound C1NCCC=2C(Cl)=C(O)C(O)=CC=2C1C1=CC=CC=C1 GHWJEDJMOVUXEC-UHFFFAOYSA-N 0.000 description 1
• HJWHHQIVUHOBQN-UHFFFAOYSA-N 9-chloro-5-phenyl-3-prop-2-enyl-1,2,4,5-tetrahydro-3-benzazepine-7,8-diol Chemical compound C1N(CC=C)CCC=2C(Cl)=C(O)C(O)=CC=2C1C1=CC=CC=C1 HJWHHQIVUHOBQN-UHFFFAOYSA-N 0.000 description 1
• 241000238876 Acari Species 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 206010000599 Acromegaly Diseases 0.000 description 1
• 206010001541 Akinesia Diseases 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• 201000000736 Amenorrhea Diseases 0.000 description 1
• 206010001928 Amenorrhoea Diseases 0.000 description 1
• USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
• 239000005695 Ammonium acetate Substances 0.000 description 1
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
• 206010002261 Androgen deficiency Diseases 0.000 description 1
• CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
• 206010067162 Asthenospermia Diseases 0.000 description 1
• 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 208000014644 Brain disease Diseases 0.000 description 1
• 208000021500 Breathing-related sleep disease Diseases 0.000 description 1
• UZUHBAKFDDAELA-UHFFFAOYSA-N C1CN(C2=CC=CC=C21)C3=NC=CC(=C3)CC4=CC(=C(C=C4)F)O Chemical compound C1CN(C2=CC=CC=C21)C3=NC=CC(=C3)CC4=CC(=C(C=C4)F)O UZUHBAKFDDAELA-UHFFFAOYSA-N 0.000 description 1
• 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
• KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 1
• SJRRQSKANIBMJG-UHFFFAOYSA-N COC1=NC=C(C=N1)CC2=CC(=NC=C2)N3CCC4=CC=CC=C43 Chemical compound COC1=NC=C(C=N1)CC2=CC(=NC=C2)N3CCC4=CC=CC=C43 SJRRQSKANIBMJG-UHFFFAOYSA-N 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 208000009132 Catalepsy Diseases 0.000 description 1
• 108091026890 Coding region Proteins 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 208000014311 Cushing syndrome Diseases 0.000 description 1
• 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
• 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 1
• 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 1
• 102100020802 D(1A) dopamine receptor Human genes 0.000 description 1
• 102100020756 D(2) dopamine receptor Human genes 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• 206010012249 Delusional disorder, erotomanic type Diseases 0.000 description 1
• 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
• 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
• 239000004375 Dextrin Substances 0.000 description 1
• 229920001353 Dextrin Polymers 0.000 description 1
• 102000004076 Dopamine D1 Receptors Human genes 0.000 description 1
• 108090000511 Dopamine D1 Receptors Proteins 0.000 description 1
• 102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
• 108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• 102100023226 Early growth response protein 1 Human genes 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 206010063006 Facial spasm Diseases 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 208000001836 Firesetting Behavior Diseases 0.000 description 1
• 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 description 1
• 201000011240 Frontotemporal dementia Diseases 0.000 description 1
• 208000001287 Galactorrhea Diseases 0.000 description 1
• 206010017600 Galactorrhoea Diseases 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 208000001613 Gambling Diseases 0.000 description 1
• 208000018522 Gastrointestinal disease Diseases 0.000 description 1
• 239000007821 HATU Substances 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 208000037357 HIV infectious disease Diseases 0.000 description 1
• 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
• 208000004095 Hemifacial Spasm Diseases 0.000 description 1
• 101000931925 Homo sapiens D(1A) dopamine receptor Proteins 0.000 description 1
• 101000931901 Homo sapiens D(2) dopamine receptor Proteins 0.000 description 1
• 101001049697 Homo sapiens Early growth response protein 1 Proteins 0.000 description 1
• 101000805515 Homo sapiens Vesicular glutamate transporter 1 Proteins 0.000 description 1
• 208000031226 Hyperlipidaemia Diseases 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• 206010021030 Hypomania Diseases 0.000 description 1
• 206010021133 Hypoventilation Diseases 0.000 description 1
• 206010021703 Indifference Diseases 0.000 description 1
• 206010022489 Insulin Resistance Diseases 0.000 description 1
• 206010022998 Irritability Diseases 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• 206010024870 Loss of libido Diseases 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 206010027304 Menopausal symptoms Diseases 0.000 description 1
• 229920000881 Modified starch Polymers 0.000 description 1
• 101000756628 Mus musculus Actin, cytoplasmic 1 Proteins 0.000 description 1
• 101100444898 Mus musculus Egr1 gene Proteins 0.000 description 1
• 101100120533 Mus musculus Fos gene Proteins 0.000 description 1
• 101500028890 Mus musculus Neurotensin Proteins 0.000 description 1
• HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
• FMJXZTQKDSNUIS-UHFFFAOYSA-N N-[4-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]pyridin-2-yl]-2,3-dihydro-1H-indole-4-carboxamide Chemical compound N1CCC=2C(=CC=CC1=2)C(=O)NC1=NC=CC(=C1)CC1=CC(=CC(=C1)C(F)(F)F)F FMJXZTQKDSNUIS-UHFFFAOYSA-N 0.000 description 1
• AVYVHIKSFXVDBG-UHFFFAOYSA-N N-benzyl-N-hydroxy-2,2-dimethylbutanamide Chemical compound C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O AVYVHIKSFXVDBG-UHFFFAOYSA-N 0.000 description 1
• QQGNLKJAIVSNCO-UHFFFAOYSA-N N-butylformamide Chemical compound CCCCNC=O QQGNLKJAIVSNCO-UHFFFAOYSA-N 0.000 description 1
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
• 239000007832 Na2SO4 Substances 0.000 description 1
• 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
• 206010029333 Neurosis Diseases 0.000 description 1
• 101800001814 Neurotensin Proteins 0.000 description 1
• 102000050267 Neurotensin Human genes 0.000 description 1
• 206010057852 Nicotine dependence Diseases 0.000 description 1
• 206010029412 Nightmare Diseases 0.000 description 1
• CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
• 206010030247 Oestrogen deficiency Diseases 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 208000035175 Oligomenorrhea Diseases 0.000 description 1
• 206010030295 Oligomenorrhoea Diseases 0.000 description 1
• 206010033122 Ovarian atrophy Diseases 0.000 description 1
• 239000002033 PVDF binder Substances 0.000 description 1
• 241000282579 Pan Species 0.000 description 1
• 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
• 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
• 208000037273 Pathologic Processes Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 240000009164 Petroselinum crispum Species 0.000 description 1
• PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
• 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
• 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
• 208000027030 Premenstrual dysphoric disease Diseases 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 208000024777 Prion disease Diseases 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 102000006478 Protein Phosphatase 2 Human genes 0.000 description 1
• 208000012545 Psychophysiologic disease Diseases 0.000 description 1
• 238000002123 RNA extraction Methods 0.000 description 1
• 239000013614 RNA sample Substances 0.000 description 1
• 101000873669 Rattus norvegicus Glutamate decarboxylase 1 Proteins 0.000 description 1
• 101000687509 Rattus norvegicus Prolactin Proteins 0.000 description 1
• 101000805513 Rattus norvegicus Vesicular glutamate transporter 1 Proteins 0.000 description 1
• 208000028665 Reactive Attachment disease Diseases 0.000 description 1
• 108091027981 Response element Proteins 0.000 description 1
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
• 102000006382 Ribonucleases Human genes 0.000 description 1
• 108010083644 Ribonucleases Proteins 0.000 description 1
• 241000282849 Ruminantia Species 0.000 description 1
• 206010039840 Secondary hypothyroidism Diseases 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 229910004298 SiO 2 Inorganic materials 0.000 description 1
• 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
• 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 240000002871 Tectona grandis Species 0.000 description 1
• 208000025569 Tobacco Use disease Diseases 0.000 description 1
• 206010043903 Tobacco abuse Diseases 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 208000031674 Traumatic Acute Stress disease Diseases 0.000 description 1
• 208000030886 Traumatic Brain injury Diseases 0.000 description 1
• 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 1
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
• 229910052770 Uranium Inorganic materials 0.000 description 1
• 206010046764 Uterine atrophy Diseases 0.000 description 1
• 241000382509 Vania Species 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 206010047853 Waxy flexibility Diseases 0.000 description 1
• 208000021017 Weight Gain Diseases 0.000 description 1
• BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
• PCBOWMZAEDDKNH-HOTGVXAUSA-N [4-(trifluoromethoxy)phenyl]methyl (3as,6as)-2-(3-fluoro-4-sulfamoylbenzoyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylate Chemical compound C1=C(F)C(S(=O)(=O)N)=CC=C1C(=O)N1C[C@H]2CN(C(=O)OCC=3C=CC(OC(F)(F)F)=CC=3)C[C@@H]2C1 PCBOWMZAEDDKNH-HOTGVXAUSA-N 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 208000026345 acute stress disease Diseases 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 239000012790 adhesive layer Substances 0.000 description 1
• 206010001584 alcohol abuse Diseases 0.000 description 1
• 208000025746 alcohol use disease Diseases 0.000 description 1
• 208000028505 alcohol-related disease Diseases 0.000 description 1
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 231100000540 amenorrhea Toxicity 0.000 description 1
• 125000003368 amide group Chemical group 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 150000001413 amino acids Chemical group 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 229960003036 amisulpride Drugs 0.000 description 1
• NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 description 1
• 229940043376 ammonium acetate Drugs 0.000 description 1
• 235000019257 ammonium acetate Nutrition 0.000 description 1
• 239000000908 ammonium hydroxide Substances 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 239000003708 ampul Substances 0.000 description 1
• 210000003484 anatomy Anatomy 0.000 description 1
• 230000002513 anti-ovulatory effect Effects 0.000 description 1
• 230000000692 anti-sense effect Effects 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 230000003078 antioxidant effect Effects 0.000 description 1
• 208000024823 antisocial personality disease Diseases 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000012736 aqueous medium Substances 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• 229960004372 aripiprazole Drugs 0.000 description 1
• 150000004982 aromatic amines Chemical class 0.000 description 1
• 230000001623 arteriogenic effect Effects 0.000 description 1
• 235000021311 artificial sweeteners Nutrition 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• 238000000889 atomisation Methods 0.000 description 1
• 239000003693 atypical antipsychotic agent Substances 0.000 description 1
• 229940127236 atypical antipsychotics Drugs 0.000 description 1
• 238000013475 authorization Methods 0.000 description 1
• 125000002393 azetidinyl group Chemical group 0.000 description 1
• 125000004069 aziridinyl group Chemical group 0.000 description 1
• 206010003883 azoospermia Diseases 0.000 description 1
• 150000007514 bases Chemical class 0.000 description 1
• JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
• BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 230000000035 biogenic effect Effects 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 230000008512 biological response Effects 0.000 description 1
• 239000000090 biomarker Substances 0.000 description 1
• 230000036983 biotransformation Effects 0.000 description 1
• OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• 210000004958 brain cell Anatomy 0.000 description 1
• 230000003925 brain function Effects 0.000 description 1
• 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000003491 cAMP production Effects 0.000 description 1
• 238000010805 cDNA synthesis kit Methods 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 150000001723 carbon free-radicals Chemical class 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 238000010531 catalytic reduction reaction Methods 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 210000001159 caudate nucleus Anatomy 0.000 description 1
• 230000006037 cell lysis Effects 0.000 description 1
• 239000006285 cell suspension Substances 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 230000003727 cerebral blood flow Effects 0.000 description 1
• REHAKLRYABHSQJ-KDOFPFPSSA-N chembl28338 Chemical compound OC1=C(O)C=C2[C@H]3C(C=C(S4)CCC)=C4CN[C@@H]3CCC2=C1 REHAKLRYABHSQJ-KDOFPFPSSA-N 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 235000013330 chicken meat Nutrition 0.000 description 1
• 125000004775 chlorodifluoromethyl group Chemical group FC(F)(Cl)* 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
• 230000027288 circadian rhythm Effects 0.000 description 1
• 229960004170 clozapine Drugs 0.000 description 1
• QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
• 230000008045 co-localization Effects 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 239000003184 complementary RNA Substances 0.000 description 1
• 239000000306 component Substances 0.000 description 1
• 229940125797 compound 12 Drugs 0.000 description 1
• 229940125833 compound 23 Drugs 0.000 description 1
• 229940127204 compound 29 Drugs 0.000 description 1
• 229940127573 compound 38 Drugs 0.000 description 1
• 235000009508 confectionery Nutrition 0.000 description 1
• 108091036078 conserved sequence Proteins 0.000 description 1
• 238000001816 cooling Methods 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• 210000000877 corpus callosum Anatomy 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 239000012043 crude product Substances 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 238000007405 data analysis Methods 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 238000000354 decomposition reaction Methods 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 238000000326 densiometry Methods 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 239000002274 desiccant Substances 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 229960000633 dextran sulfate Drugs 0.000 description 1
• 235000019425 dextrin Nutrition 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 150000001989 diazonium salts Chemical class 0.000 description 1
• 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• 229940043237 diethanolamine Drugs 0.000 description 1
• 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
• IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
• 239000012470 diluted sample Substances 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 150000002009 diols Chemical class 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• LBOJYSIDWZQNJS-CVEARBPZSA-N dizocilpine Chemical compound C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 LBOJYSIDWZQNJS-CVEARBPZSA-N 0.000 description 1
• QLTXKCWMEZIHBJ-PJGJYSAQSA-N dizocilpine maleate Chemical compound OC(=O)\C=C/C(O)=O.C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 QLTXKCWMEZIHBJ-PJGJYSAQSA-N 0.000 description 1
• FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
• 229960001253 domperidone Drugs 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 238000009510 drug design Methods 0.000 description 1
• 238000002651 drug therapy Methods 0.000 description 1
• 201000006549 dyspepsia Diseases 0.000 description 1
• 239000008157 edible vegetable oil Substances 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 229960005139 epinephrine Drugs 0.000 description 1
• 238000012869 ethanol precipitation Methods 0.000 description 1
• GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 1
• 229940012017 ethylenediamine Drugs 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 239000013604 expression vector Substances 0.000 description 1
• 239000011536 extraction buffer Substances 0.000 description 1
• 230000004424 eye movement Effects 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
• 125000001207 fluorophenyl group Chemical group 0.000 description 1
• 239000006260 foam Substances 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 210000005153 frontal cortex Anatomy 0.000 description 1
• 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
• 239000003349 gelling agent Substances 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 108010024847 glutamate decarboxylase 1 Proteins 0.000 description 1
• 108010078430 glutamine phenylacetyltransferase Proteins 0.000 description 1
• 235000011187 glycerol Nutrition 0.000 description 1
• 238000000227 grinding Methods 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 150000004820 halides Chemical class 0.000 description 1
• 125000004438 haloalkoxy group Chemical group 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 125000005241 heteroarylamino group Chemical group 0.000 description 1
• 239000008240 homogeneous mixture Substances 0.000 description 1
• 230000003054 hormonal effect Effects 0.000 description 1
• 102000057295 human GPR52 Human genes 0.000 description 1
• 102000045585 human SLC17A7 Human genes 0.000 description 1
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
• 229960000930 hydroxyzine Drugs 0.000 description 1
• 208000013403 hyperactivity Diseases 0.000 description 1
• 201000001421 hyperglycemia Diseases 0.000 description 1
• 239000003326 hypnotic agent Substances 0.000 description 1
• 230000002267 hypothalamic effect Effects 0.000 description 1
• 230000002989 hypothyroidism Effects 0.000 description 1
• 239000005457 ice water Substances 0.000 description 1
• 238000005286 illumination Methods 0.000 description 1
• 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
• 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 239000005414 inactive ingredient Substances 0.000 description 1
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 239000003999 initiator Substances 0.000 description 1
• 229940102223 injectable solution Drugs 0.000 description 1
• 229940102213 injectable suspension Drugs 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 208000015046 intermittent explosive disease Diseases 0.000 description 1
• 230000004068 intracellular signaling Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 230000026045 iodination Effects 0.000 description 1
• 238000006192 iodination reaction Methods 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 230000002427 irreversible effect Effects 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• SANOUVWGPVYVAV-UHFFFAOYSA-N isovaleramide Chemical compound CC(C)CC(N)=O SANOUVWGPVYVAV-UHFFFAOYSA-N 0.000 description 1
• 239000000231 karaya gum Substances 0.000 description 1
• 235000010494 karaya gum Nutrition 0.000 description 1
• 206010023461 kleptomania Diseases 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 239000012280 lithium aluminium hydride Substances 0.000 description 1
• 238000012153 long-term therapy Methods 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
• 239000001095 magnesium carbonate Substances 0.000 description 1
• 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 238000011418 maintenance treatment Methods 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 229940126601 medicinal product Drugs 0.000 description 1
• 229960003194 meglumine Drugs 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 230000006996 mental state Effects 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 229940071648 metered dose inhaler Drugs 0.000 description 1
• OBKSTEOVEUUBBH-UHFFFAOYSA-N methyl 3-(dibenzylamino)-2-fluoropropanoate Chemical compound C=1C=CC=CC=1CN(CC(F)C(=O)OC)CC1=CC=CC=C1 OBKSTEOVEUUBBH-UHFFFAOYSA-N 0.000 description 1
• 238000007069 methylation reaction Methods 0.000 description 1
• 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
• 239000013081 microcrystal Substances 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 230000000116 mitigating effect Effects 0.000 description 1
• 235000019426 modified starch Nutrition 0.000 description 1
• 125000002757 morpholinyl group Chemical group 0.000 description 1
• 210000000214 mouth Anatomy 0.000 description 1
• 239000002324 mouth wash Substances 0.000 description 1
• DYGBNAYFDZEYBA-UHFFFAOYSA-N n-(cyclopropylmethyl)-2-[4-(4-methoxybenzoyl)piperidin-1-yl]-n-[(4-oxo-1,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-2-yl)methyl]acetamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(CC(=O)N(CC2CC2)CC=2NC(=O)C=3COCCC=3N=2)CC1 DYGBNAYFDZEYBA-UHFFFAOYSA-N 0.000 description 1
• NRMJMIGWXUCEEW-UHFFFAOYSA-N n-butan-2-ylformamide Chemical compound CCC(C)NC=O NRMJMIGWXUCEEW-UHFFFAOYSA-N 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• KERBAAIBDHEFDD-UHFFFAOYSA-N n-ethylformamide Chemical compound CCNC=O KERBAAIBDHEFDD-UHFFFAOYSA-N 0.000 description 1
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
• KVTGAKFJRLBHLU-UHFFFAOYSA-N n-propan-2-ylformamide Chemical compound CC(C)NC=O KVTGAKFJRLBHLU-UHFFFAOYSA-N 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• SUUDTPGCUKBECW-UHFFFAOYSA-N n-propylformamide Chemical compound CCCNC=O SUUDTPGCUKBECW-UHFFFAOYSA-N 0.000 description 1
• SDLAKRCBYGZJRW-UHFFFAOYSA-N n-tert-butylformamide Chemical compound CC(C)(C)NC=O SDLAKRCBYGZJRW-UHFFFAOYSA-N 0.000 description 1
• 201000003631 narcolepsy Diseases 0.000 description 1
• 235000021096 natural sweeteners Nutrition 0.000 description 1
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 1
• 208000015238 neurotic disease Diseases 0.000 description 1
• 239000002858 neurotransmitter agent Substances 0.000 description 1
• 230000008452 non REM sleep Effects 0.000 description 1
• 231100000344 non-irritating Toxicity 0.000 description 1
• 239000012457 nonaqueous media Substances 0.000 description 1
• 238000010606 normalization Methods 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 210000001009 nucleus accumben Anatomy 0.000 description 1
• 235000016709 nutrition Nutrition 0.000 description 1
• 230000035764 nutrition Effects 0.000 description 1
• 208000001797 obstructive sleep apnea Diseases 0.000 description 1
• 229960005017 olanzapine Drugs 0.000 description 1
• KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
• 229940049964 oleate Drugs 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 210000000956 olfactory bulb Anatomy 0.000 description 1
• 210000001010 olfactory tubercle Anatomy 0.000 description 1
• 208000008634 oligospermia Diseases 0.000 description 1
• PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 239000006186 oral dosage form Substances 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 231100001043 ovarian atrophy Toxicity 0.000 description 1
• 208000015124 ovarian disease Diseases 0.000 description 1
• 201000004535 ovarian dysfunction Diseases 0.000 description 1
• 231100000543 ovarian dysfunction Toxicity 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 239000004031 partial agonist Substances 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 230000009054 pathological process Effects 0.000 description 1
• 239000001814 pectin Substances 0.000 description 1
• 235000010987 pectin Nutrition 0.000 description 1
• 229920001277 pectin Polymers 0.000 description 1
• 235000019371 penicillin G benzathine Nutrition 0.000 description 1
• 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 235000011197 perejil Nutrition 0.000 description 1
• 239000002831 pharmacologic agent Substances 0.000 description 1
• 208000007100 phencyclidine abuse Diseases 0.000 description 1
• 150000002989 phenols Chemical class 0.000 description 1
• 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 108091005981 phosphorylated proteins Proteins 0.000 description 1
• 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 208000010916 pituitary tumor Diseases 0.000 description 1
• 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
• 210000002975 pon Anatomy 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 229910000027 potassium carbonate Inorganic materials 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 230000002360 prefrontal effect Effects 0.000 description 1
• 206010036596 premature ejaculation Diseases 0.000 description 1
• 238000002953 preparative HPLC Methods 0.000 description 1
• 238000012746 preparative thin layer chromatography Methods 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 230000003518 presynaptic effect Effects 0.000 description 1
• 230000003449 preventive effect Effects 0.000 description 1
• 238000009117 preventive therapy Methods 0.000 description 1
• 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
• 235000019833 protease Nutrition 0.000 description 1
• 235000019419 proteases Nutrition 0.000 description 1
• 238000002731 protein assay Methods 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 201000004645 pyromania Diseases 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
• 229950001518 raclopride Drugs 0.000 description 1
• 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
• 208000019969 rapid eye movement sleep disease Diseases 0.000 description 1
• 229940075993 receptor modulator Drugs 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 239000013557 residual solvent Substances 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 239000012723 sample buffer Substances 0.000 description 1
• 238000007789 sealing Methods 0.000 description 1
• 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 230000010332 selective attention Effects 0.000 description 1
• 238000011894 semi-preparative HPLC Methods 0.000 description 1
• 210000001625 seminal vesicle Anatomy 0.000 description 1
• 238000012154 short term therapy Methods 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 229910052709 silver Inorganic materials 0.000 description 1
• 239000004332 silver Substances 0.000 description 1
• 201000002859 sleep apnea Diseases 0.000 description 1
• 230000004599 slow eye movement Effects 0.000 description 1
• 230000000391 smoking effect Effects 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 239000012279 sodium borohydride Substances 0.000 description 1
• 229910000033 sodium borohydride Inorganic materials 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• AIDBEARHLBRLMO-UHFFFAOYSA-M sodium;dodecyl sulfate;2-morpholin-4-ylethanesulfonic acid Chemical compound [Na+].OS(=O)(=O)CCN1CCOCC1.CCCCCCCCCCCCOS([O-])(=O)=O AIDBEARHLBRLMO-UHFFFAOYSA-M 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 230000006886 spatial memory Effects 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 238000013222 sprague-dawley male rat Methods 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 239000011550 stock solution Substances 0.000 description 1
• 208000035458 subtype of a disease Diseases 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 239000002278 tabletting lubricant Substances 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 230000000542 thalamic effect Effects 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 230000004797 therapeutic response Effects 0.000 description 1
• 125000001113 thiadiazolyl group Chemical group 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 231100000563 toxic property Toxicity 0.000 description 1
• 231100000583 toxicological profile Toxicity 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 239000006163 transport media Substances 0.000 description 1
• 230000009529 traumatic brain injury Effects 0.000 description 1
• 125000004306 triazinyl group Chemical group 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
• 229940029284 trichlorofluoromethane Drugs 0.000 description 1
• 208000002271 trichotillomania Diseases 0.000 description 1
• 125000004360 trifluorophenyl group Chemical group 0.000 description 1
• IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
• 231100001042 uterine atrophy Toxicity 0.000 description 1
• 208000019553 vascular disease Diseases 0.000 description 1
• 201000010653 vesiculitis Diseases 0.000 description 1
• 239000011345 viscous material Substances 0.000 description 1
• 230000016776 visual perception Effects 0.000 description 1
• 238000007794 visualization technique Methods 0.000 description 1
• 230000003313 weakening effect Effects 0.000 description 1
• 230000004584 weight gain Effects 0.000 description 1
• 235000019786 weight gain Nutrition 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 239000008096 xylene Substances 0.000 description 1
• GQDDNDAYOVNZPG-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C[C]2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3N=C21 GQDDNDAYOVNZPG-SCYLSFHTSA-N 0.000 description 1
• 229960000317 yohimbine Drugs 0.000 description 1
• AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1
• 229960000607 ziprasidone Drugs 0.000 description 1
• MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1